Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

407 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Benefits and risks of prostate cancer screening.
Fornara P, Theil G, Schaefer C, Heß J, Rübben H. Fornara P, et al. Oncol Res Treat. 2014;37 Suppl 3:29-37. doi: 10.1159/000363756. Epub 2014 Aug 29. Oncol Res Treat. 2014. PMID: 25195830 No abstract available.
Prognostic value of tissue and circulating levels of IMP3 in prostate cancer.
Szarvas T, Tschirdewahn S, Niedworok C, Kramer G, Sevcenco S, Reis H, Shariat SF, Rübben H, vom Dorp F. Szarvas T, et al. Int J Cancer. 2014 Oct 1;135(7):1596-604. doi: 10.1002/ijc.28808. Epub 2014 Mar 4. Int J Cancer. 2014. PMID: 24615121
PSA quo vadis? It is reasonable to start with prostate-specific antigen testing at the age of 40!
Börgermann C, vom Dorp F, Swoboda A, Ketteniss O, Becker M, Rübben H. Börgermann C, et al. Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1190-5. doi: 10.1158/1055-9965.EPI-10-1198. Epub 2011 Mar 29. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21447776
Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer.
Szarvas T, Jäger T, Becker M, Tschirdewahn S, Niedworok C, Kovalszky I, Rübben H, Ergün S, vom Dorp F. Szarvas T, et al. Pathol Oncol Res. 2011 Jun;17(2):325-32. doi: 10.1007/s12253-010-9320-4. Epub 2011 Jan 21. Pathol Oncol Res. 2011. PMID: 21253919
Serum Chromogranin A as a Complementary Marker for the Prediction of Prostate Cancer-Specific Survival.
Niedworok C, Tschirdewahn S, Reis H, Lehmann N, Szücs M, Nyirády P, Romics I, Rübben H, Szarvas T. Niedworok C, et al. Pathol Oncol Res. 2017 Jul;23(3):643-650. doi: 10.1007/s12253-016-0171-5. Epub 2016 Dec 23. Pathol Oncol Res. 2017. PMID: 28012116
The prognostic value of cadherin switch in bladder cancer.
Jäger T, Becker M, Eisenhardt A, Tilki D, Tötsch M, Schmid KW, Romics I, Rübben H, Ergün S, Szarvas T. Jäger T, et al. Oncol Rep. 2010 Apr;23(4):1125-32. doi: 10.3892/or_00000741. Oncol Rep. 2010. PMID: 20204300
Serum levels of angiogenic factors and their prognostic relevance in bladder cancer.
Szarvas T, Jäger T, Droste F, Becker M, Kovalszky I, Romics I, Ergün S, Rübben H. Szarvas T, et al. Pathol Oncol Res. 2009 Jun;15(2):193-201. doi: 10.1007/s12253-008-9107-z. Epub 2008 Sep 20. Pathol Oncol Res. 2009. PMID: 18807212
[Informed consent for patients on early recognition of prostate carcinoma is insufficient].
Börgermann C, vom Dorp F, Rossi R, Schenck M, Luboldt HJ, Rübben H. Börgermann C, et al. Urologe A. 2009 Sep;48(9):997-8, 1000-1. doi: 10.1007/s00120-009-2074-5. Urologe A. 2009. PMID: 19680621 German.
407 results
Jump to page
Feedback